Sign in

You're signed outSign in or to get full access.

Jeff Needles

Chief Financial Officer at Lazydays Holdings
Executive

About Jeff Needles

Jeff Needles, age 48, is Chief Financial Officer and Corporate Secretary of Lazydays Holdings, Inc. (Nasdaq: GORV) since January 6, 2025; he is a CPA with an MBA from Washington University and a BSBA from Saint Louis University’s John Cook School of Business . Prior roles include CFO positions in marine manufacturing and HVAC, and finance leadership posts in logistics and powersports, bringing FP&A, cost analysis, and operational efficiency expertise . Company performance context under his tenure shows improved Q1 2025 margins and deleveraging, following a challenging FY2024 with negative TSR and a net loss; Lazydays executed a 1-for-30 reverse split in July 2025 to address Nasdaq bid-price compliance .

Company performance context:

MetricPeriodValue
Revenue ($USD Millions)Q1 2025$165.8
Gross Profit Margin (%)Q1 202526.4%
Net Loss ($USD Millions)Q1 2025$(9.5)
TSR – $100 initial investment (Year-end value)FY 2024$4.43
Net Income (Loss) ($USD Millions)FY 2024$(163.7)

Past Roles

OrganizationRoleYearsStrategic Impact
Warbird Marine Holdings (Yellowfin/Invincible)Chief Financial OfficerMay 2020–Jan 2025Led finance for multi-location marine OEM; FP&A, operational efficiency
United Enertech (PE-owned HVAC manufacturer)Chief Financial OfficerJan 2017–May 2020Cost analysis, financing, and operational improvements
Schnellecke Logistics USA; Mastercraft Boat Co.; Harley-Davidson Motor Co.Finance leadership rolesPrior to 2017Financial management in logistics and powersports, operational effectiveness

External Roles

OrganizationRoleYearsNotes
No public company directorships disclosed

Fixed Compensation

ComponentTermsAmount/Detail
Base SalaryAnnual$350,000
Target Annual Bonus% of base; STIP50% of base salary; payout range set annually (0–150% of target)
2025 Minimum BonusGuaranteed threshold≥$87,500 (50% of target) if employed through payment date
BenefitsStandard plansEligible per company plans; reimbursement for initial health coverage if benefits start later
RelocationLump sum$30,000; clawback if resignation/termination for cause before Dec 31, 2026
Housing AllowanceTemporary$2,500/month for first six months of 2025 (taxable)

Performance Compensation

Annual equity awards target 50% of base, split evenly between time-based RSUs and EPS-linked performance equity, granted under the Amended & Restated 2018 LTIP at Board/Comp Committee discretion .

Incentive TypeMetricWeightingTarget/PayoutVesting
Time-based equity (RSUs/options)Service50% of annual equityTarget grant ≥ 25% of base salary (half of total equity target)1/3 per year over 3 years from grant date
Performance-based equityEarnings per share over 3 years50% of annual equityThreshold 50% of target; max 2x target; vest only at end of 3-year term if goals metCliff vest at end of 3-year performance period
Plan mechanics (LTIP)Multiple measures permissible (EBITDA, adjusted EBITDA, TSR, stock price, ROIC, etc.)As set by CommitteeCommittee discretion each cyclePer award agreements
Change-in-controlCompany-level eventUnvested awards accelerate unless award agreement specifies otherwiseImmediate vesting upon CoC

Clawback policy: SEC/Nasdaq-compliant; following the FY2024 restatement, the Company’s recovery analysis found no erroneously awarded incentive compensation requiring recoupment .

Equity Ownership & Alignment

ItemDetail
Beneficial Ownership0 shares reported as of June 10, 2025; <1% of class
Vested/Unvested EquityIndividual award details for Needles not disclosed; annual grants typically issued Mar/Apr
Options (Exercisable/Unexercisable)Not disclosed for Needles; overall 2018 Plan outstanding options 1,732,768 at 12/31/2024
Stock Ownership GuidelinesCFO required to hold stock equal to 3x base salary; shares, unexercised options, unvested RSUs count; expected to achieve within 3 years of April 2022 adoption
Hedging/PledgingHedging and short sales prohibited; pledging not specifically disclosed

Employment Terms

ProvisionTerms
Start Date; RoleJanuary 6, 2025; CFO & Corporate Secretary; reports to CEO
Termination (Company without Cause or Resignation for Good Reason)Severance equal to 12 months base salary, payable in installments; COBRA reimbursement (12 months difference to employee rate); service deemed to continue 18 months for vesting purposes on outstanding equity; subject to signed release
Good ReasonMaterial diminution of authority/duties or material breach by Company, subject to notice/cure
Non-Compete12 months post-termination; RV dealership business in geographies where Company operates
Non-Solicit12 months post-termination; employees and customers
Confidentiality/Non-DisparagementOngoing; injunctive relief available for breach
Governing Law/VenueFlorida; jury trial waived
Insider Trading/Ownership PoliciesAcknowledges and must comply; stock ownership/holding requirements
Change-in-Control (Plan-level)Unvested LTIP awards accelerate upon CoC unless otherwise specified

Performance & Track Record

AreaEvidence
Q1 2025 operational improvementsGross profit margin rose to 26.4% with improved margins across product lines; loss from operations narrowed; deleveraging via ~$145M debt repayment following divestitures
FY2024 baselineNet loss $(163.7)M; TSR indicator—$100 investment worth $4.43 at 2024 year-end; significant impairments and high interest costs
Capital actionsRights offering (Feb 2025); PIPE and preferred exchange (Nov–Dec 2024); 1-for-30 reverse split (July 2025); bid-price deficiency disclosed Jan 2025

Governance & Compensation Oversight

TopicDetail
Compensation CommitteeDeVincenzi (Chair), Comstock, Fredlake; met nine times in 2024
Clawback PolicyAdopted per SEC/Nasdaq; no recovery required post-2024 restatement
Say-on-Pay cadenceNext advisory vote scheduled for 2027 annual meeting

Risk Indicators & Red Flags

  • Financial reporting restatement (FY2024) and identified material weaknesses in ITGCs and staffing; going-concern disclosure citing liquidity constraints and reduced revolver access .
  • Nasdaq bid-price deficiency noted Jan 2025; reverse split executed July 2025 to regain compliance .
  • Concentrated ownership and related-party term loan (Coliseum), with warrants and cross-default provisions; higher-cost debt .

Investment Implications

  • Alignment: Needles’ pay mix emphasizes multi-year EPS-based vesting and stock ownership guidelines (3x salary), supporting pay-for-performance; LTIP change-in-control single-trigger acceleration is a potential overhang in event-driven scenarios .
  • Retention and selling pressure: Severance (12 months base) and 18-month deemed service for vesting mitigate near-term forced selling; 12-month non-compete/non-solicit increase retention costs if departure occurs .
  • Skin-in-the-game: No beneficial ownership reported as of June 10, 2025; with annual equity grants and guidelines counting unvested awards, expect ownership to build, but current visibility is limited .
  • Execution risk vs. turnaround: Q1 2025 margin improvements and debt reduction are positives, but material weaknesses, going-concern, and capital structure (variable-rate floorplan, related-party term loan) heighten risk; reverse split and bid-price issues indicate ongoing market instability .